Progyny (NASDAQ:PGNY) EVP Allison Swartz Sells 1,199 Shares

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 1,199 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total value of $29,998.98. Following the completion of the sale, the executive vice president directly owned 83,316 shares in the company, valued at approximately $2,084,566.32. The trade was a 1.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Allison Swartz also recently made the following trade(s):

• On Thursday, June 4th, Allison Swartz sold 599 shares of Progyny stock. The shares were sold at an average price of $25.08, for a total value of $15,022.92.

Progyny Stock Up 1.5%

Shares of NASDAQ PGNY opened at $25.86 on Friday. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 33.58, a PEG ratio of 2.25 and a beta of 1.03. Progyny, Inc. has a 52-week low of $16.10 and a 52-week high of $28.75. The business’s 50 day moving average is $20.58 and its two-hundred day moving average is $22.30.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Analysts anticipate that Progyny, Inc. will post 1.07 EPS for the current fiscal year.

Progyny announced that its Board of Directors has initiated a share repurchase plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 10.3% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on PGNY shares. Citizens Jmp boosted their target price on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Monday, May 11th. Barclays boosted their price target on shares of Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. KeyCorp dropped their price target on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Finally, Canaccord Genuity Group upgraded shares of Progyny from a “hold” rating to a “buy” rating and boosted their price target for the stock from $19.00 to $30.00 in a research note on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.67.

Hedge Funds Weigh In On Progyny

Several institutional investors have recently modified their holdings of PGNY. Wellington Management Group LLP grew its stake in shares of Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after acquiring an additional 1,621,688 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Progyny by 46.9% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Progyny during the fourth quarter worth $19,917,000. Barclays PLC grew its stake in shares of Progyny by 79.2% during the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after purchasing an additional 696,447 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.